Document:

Exhibit
4.2

 

Form
of Representative’s Warrant Agreement

 

THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER
THAN (I) EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR
(II) A BONA FIDE OFFICER OR PARTNER OF EF HUTTON, DIVISION OF BENCHMARK INVESTMENTS, LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS SIX MONTHS FROM THE EFFECTIVE DATE OF THE OFFERING].
VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].

 

COMMON
STOCK PURCHASE WARRANT

 

For
the Purchase of [__] Shares of Common Stock

of

EMULATE
THERAPEUTICS, INC.

 

1.
Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of EF Hutton, division of Benchmark
Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, EMulate Therapeutics, Inc., a Washington
corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________] [DATE
THAT IS SIX MONTHS FROM THE EFFECTIVE DATE OF THE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m.,
Eastern time, [____________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the “Expiration Date”),
but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [__] shares of common stock of the Company, par
value $0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date
is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding
day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees
not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[__] per Share;
provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this
Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted
as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price,
depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement
on Form S-1 (File No. 333-[●]) of the Company was declared effective by the Securities and Exchange Commission.

 

2.
Exercise.

 

2.1
Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed
and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased payable
in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank
check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date,
this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.

 

    	A-2

     

    

 

2.2
Cashless Exercise. If at any time after the Commencement Date there is no effective registration statement registering, or no
current prospectus available for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment
of cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares
equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company,
together with the exercise form attached hereto, in which event the Company shall issue to Holder, Shares in accordance with the following
formula:

 

	X	=	Y(A-B)	 
	A	 

 

	Where,	 	 	 
	 	X	=	The
    number of Shares to be issued to Holder;
	 	Y	=	The
    number of Shares for which the Purchase Warrant is being exercised;
	 	A	=	The
    fair market value of one Share; and
	 	B	=	The
    Exercise Price.

 

For
purposes of this Section 2.2, the fair market value of a Share is defined as follows:

 

	 	(i)	if
    the Company’s common stock is traded on a securities exchange, the value shall be deemed to be the closing price on such exchange
    prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; or
	 	 	 
	 	(ii)	if
    the Company’s common stock is actively traded over-the-counter, the value shall be deemed to be the closing bid price prior
    to the exercise form being submitted in connection with the exercise of the Purchase Warrant; if there is no active public market,
    the value shall be the fair market value thereof, as determined in good faith by the Company’s Board of Directors.

 

2.3
Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the “Securities Act”):

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR APPLICABLE STATE LAW. NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT AND APPLICABLE STATE LAW WHICH, IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE.”

 

3.
Transfer.

 

3.1
General Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder
will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant or the securities issuable hereunder for a period of
one hundred eighty (180) days following the Effective Date to anyone other than: (i) EF Hutton, division of Benchmark Investments, LLC
(“EF Hutton”) or an underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or
partner of EF Hutton or of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(e)(1), or
(b) for a period of one hundred eighty (180) days following the Effective Date, cause this Purchase Warrant or the securities issuable
hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). On and after one hundred
eighty (180) days after the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable
securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto
duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith.
The Company shall within five (5) business days transfer this Purchase Warrant on the books of the Company and shall execute and deliver
a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the
aggregate number of Shares purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.

 

    	A-3

     

    

 

3.2
Restrictions Imposed by the Securities Act. The securities evidenced by this Purchase Warrant shall not be transferred unless
and until: (i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption
from registration under the Securities Act and applicable state securities laws, the availability of which is established to the reasonable
satisfaction of the Company (the Company hereby agreeing that the opinion of Seward & Kissel LLP shall be deemed satisfactory evidence
of the availability of an exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating
to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities and Exchange Commission
(the “Commission”) and compliance with applicable state securities law has been established.

 

4.
Registration Rights.

 

4.1
Demand Registration.

 

4.1.1
Grant of Right. The Company, upon written demand (a “Demand Notice”) of the Holders of at least 51% of the
Purchase Warrants and/or the underlying Shares, agrees to register, on one (1) occasion, all or any portion of the Shares underlying
the Purchase Warrants (collectively, the “Registrable Securities”). On such occasion, the Company will file a registration
statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its
reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance with review
by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company
has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section
4.2 hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or (ii) if such
registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration
statement has been withdrawn or until thirty (30) days after such offering is consummated. The Company covenants and agrees to give written
notice of its receipt of any Demand Notice by any Holders to all other registered Holders of the Purchase Warrants and/or the Registrable
Securities within ten (10) days after the date of the receipt of any such Demand Notice.

 

4.1.2
Terms. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section
4.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause
the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such states as are reasonably
requested by the Holders; provided, however, that in no event shall the Company be required to register the Registrable
Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in
such State or submit to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to
escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand
right granted under Section 4.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the
Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities.
The Holders shall only use the prospectuses provided by the Company to sell the shares covered by such registration statement, and will
immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer
be used due to a material misstatement or omission. Notwithstanding the provisions of this Section 4.1.2, the Holder shall be entitled
to a demand registration under this Section 4.1.2 on only one (1) occasion and such demand registration right shall terminate on the
fifth anniversary of the Effective Date in accordance with FINRA Rule 5110(g)(8)(C).

 

    	A-4

     

    

 

4.2
“Piggy-Back” Registration.

 

4.2.1
Grant of Right. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right,
for a period of no more than seven (7) years from the Effective Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable
Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated
by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or Form S-4 or any equivalent form); provided, however,
that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s)
thereof shall, in its reasonable discretion, impose a limitation on the number of shares of common stock which may be included in the
Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary
to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion
of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit.
Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion
to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall
not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not
entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable
Securities.

 

4.2.2
Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1
hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders
to represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days’ written notice prior
to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the
Registrable Securities shall exercise the “piggy-back” rights provided for herein by giving written notice within ten (10)
days of the receipt of the Company’s notice of its intention to file a registration statement. Except as otherwise provided in
this Purchase Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.2.2; provided,
however, that such registration rights shall terminate on the fifth anniversary of the Commencement Date.

 

4.3
General Terms.

 

4.3.1
Indemnification. The Company shall indemnify the Holders of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section
20(a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and
other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become
subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent
and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section
5.1 of the Underwriting Agreement between the Underwriters and the Company, dated as of [___________], 2022. The Holders of the Registrable
Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify
the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses
reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the
Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors
or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions
contained in Section 5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.

 

4.3.2
Exercise of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holders to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

    	A-5

     

    

 

4.3.3
Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings and to
each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel
to the Company, dated the Effective Date of such registration statement (and, if such registration includes an underwritten public offering,
an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter
dated the Effective Date of such registration statement (and, if such registration includes an underwritten public offering, a letter
dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has
issued a report on the Company’s financial statements included in such registration statement, in each case covering substantially
the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’
letter, with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s
counsel and in accountants’ letters delivered to underwriters in underwritten public offerings of securities. The Company shall
also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to
the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or the Auditor and
all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder
and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the
registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
the Auditor, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.

 

4.3.4
Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected
by any Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such
managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily
contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating
to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties
and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their Shares and their intended methods of distribution.

 

4.3.5
Documents to be Delivered by Holders. Each of the Holders participating in any of the foregoing offerings shall furnish to the
Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders.

 

4.3.6
Damages. Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company
or the Company otherwise fails to comply with such provisions, the Holders shall, in addition to any other legal or other relief available
to the Holders, be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach
of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity
of posting bond or other security.

 

4.4
Termination of Registration Rights. The registration rights afforded to the Holders under this Section 4 shall terminate on the
earliest date when all Registrable Securities of such Holder either: (i) have been publicly sold by such Holder pursuant to a Registration
Statement, (ii) have been covered by an effective Registration Statement on Form S-1 or Form S-3 (or successor form), which may be kept
effective as an evergreen Registration Statement, or (iii) may be sold by the Holder within a 90 day period without registration pursuant
to Rule 144 or consistent with applicable SEC interpretive guidance (including CD&I no. 201.04 (April 2, 2007) or similar interpretive
guidance).

 

5.
New Purchase Warrants to be Issued.

 

5.1
Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned
in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised
pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor
to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder
as to which this Purchase Warrant has not been exercised or assigned.

 

    	A-6

     

    

 

5.2
Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver
a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft,
mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

6.
Adjustments.

 

6.1
Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase Warrant
shall be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1
Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective day
thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares, and the
Exercise Price shall be proportionately decreased.

 

6.1.2
Aggregation of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the Effective Date
thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding Shares, and the
Exercise Price shall be proportionately increased.

 

6.1.3
Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding Shares
other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case of any
share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or
share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the property
of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase
Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the
exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares
of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction
or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of Shares of
the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results
in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections 6.1.1, 6.1.2 and this
Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share reconstructions
or amalgamations, or consolidations, sales or other transfers.

 

6.1.4
Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this
Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated
in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants
reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement
Date or the computation thereof.

 

6.2
Substitute Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the
Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in
any reclassification or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation
shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding
or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise
of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation
or share reconstruction or amalgamation, by a holder of the number of Shares for which such Purchase Warrant might have been exercised
immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall
provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section
shall similarly apply to successive consolidations or share reconstructions or amalgamations.

 

    	A-7

     

    

 

6.3
Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares
upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it
being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may
be, to the nearest whole number of Shares or other securities, properties or rights.

 

7.
Reservation and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the
purpose of issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall
be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the
Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly
and validly issued, fully paid and non-assessable and not subject to preemptive rights of any stockholder. As long as the Purchase Warrants
shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable upon exercise of the Purchase
Warrants to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin
Board or any successor trading market) on which the Shares issued to the public in the Offering may then be listed and/or quoted.

 

8.
Certain Notice Requirements.

 

8.1
Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or
consent or to receive notice as a stockholder for the election of directors or any other matter, or as having any rights whatsoever as
a stockholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the
events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination of
the stockholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to
vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing
of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice
given to the other stockholders of the Company at the same time and in the same manner that such notice is given to the stockholders.

 

8.2
Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the
following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a
dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company; (ii) the Company shall offer to
all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable for
shares of capital stock of the Company, or any option, right or warrant to subscribe therefor; or (iii) a dissolution, liquidation or
winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of all or
substantially all of its property, assets and business shall be proposed.

 

8.3
Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant
to Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s
Chief Executive Officer or Chief Financial Officer.

 

    	A-8

     

    

 

8.4
Transmittal of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing
and shall be deemed to have been duly made when hand delivered or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to the
following address or to such other address as the Company may designate by notice to the Holders:

 

If
to the Holder:

 

EF
Hutton

590
Madison Avenue, 39th Floor

New
York, New York 10022

Attn:
Joseph T. Rallo

 

with
a copy (which shall not constitute notice) to:

 

Seward
& Kissel LLP

One
Battery Park Plaza

New
York, New York 10004

Attn:
Keith Billotti

Email:
billotti@sewkis.com

 

If
to the Company:

 

EMulate
Therapeutics, Inc.

13810
SE Eastgate Way, Suite 560

Bellevue,
Washington 98005

Attn:
Chris Rivera

Email:
crivera@emulatetx.com

 

with
a copy (which shall not constitute notice) to:

 

Lucosky
Brookman LLP

101
Wood Avenue South

5th
Floor

Iselin,
NJ 08830

Attn:
Joseph M. Lucosky, Esq.

Email:
jlucosky@lucbro.com

 

9.
Miscellaneous.

 

9.1
Amendments. The Company and EF Hutton may from time to time supplement or amend this Purchase Warrant without the approval of
any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent
with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company
and EF Hutton may deem necessary or desirable and that the Company and EF Hutton deem shall not adversely affect the interest of the
Holders. All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement
of the modification or amendment is sought.

 

9.2
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3
Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

    	A-9

     

    

 

9.4
Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company
and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.

 

9.5
Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New
York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to
such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company
may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to
it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the
Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall
be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or
proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable
law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.

 

9.6
Waiver, etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall
not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any
provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver
of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach,
non-compliance or non-fulfillment.

 

9.7
Execution in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.

 

9.8
Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that,
at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and EF Hutton enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination
of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Signature
Page Follows]

 

    	A-10

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______,
2022.

 

EMULATE
THERAPEUTICS, INC.

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    	A-11

     

    

 

[Form
to be used to exercise Purchase Warrant]

 

Date:
__________, 20___

 

The
undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.001 per share
(the “Shares”), of [_________], a [_________] corporation (the “Company”), and hereby makes payment
of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this
Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing
the number of Shares for which this Purchase Warrant has not been exercised.

 

or

 

The
undersigned hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______
Shares, as determined in accordance with the following formula:

 

	X	=	Y(A-B)	 
	A	 

 

	Where,	 	 	 
	 	X	=	The
    number of Shares to be issued to Holder;
	 	Y	=	The
    number of Shares for which the Purchase Warrant is being exercised;
	 	A	=	The
    fair market value of one Share which is equal to $_____; and
	 	B	=	The
    Exercise Price which is equal to $______ per share

 

The
undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement
with respect to the calculation shall be resolved by the Company in its sole discretion.

 

Please
issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

 

	 	Signature	 	 

 

	 	Signature
    Guaranteed	 	 

 

INSTRUCTIONS
FOR REGISTRATION OF SECURITIES

 

	Name:	 	 
	 	(Print
    in Block Letters)	 

 

	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.

 

    	A-12

     

    

 

[Form
to be used to assign Purchase Warrant]

 

ASSIGNMENT

 

(To
be executed by the registered Holder to effect a transfer of the within Purchase Warrant):

 

FOR
VALUE RECEIVED, __________________ does hereby sell, assign and transfer unto the right to purchase shares of common stock, par value
$0.001 per share, of EMulate Therapeutics, Inc., a Washington corporation (the “Company”), evidenced by the Purchase
Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated:
__________, 20__

 

	Signature	 	 

 

	Signature
    Guaranteed	 	 

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or
enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm
having membership on a registered national securities exchange.

 

    	A-13Exhibit 10.1

 

BOARD OF DIRECTORS AGREEMENT

 

THIS BOARD OF DIRECTORS AGREEMENT (“Agreement”)
is made and entered into as of November 11, 2022 (“Signing Date”) and effective as of the date the Company became publicly
traded, September 27, 2022 (the “Effective Date”), by and between Atlis Motor Vehicles, Inc., a Delaware corporation
(the “Company”) with its principal place of business located at 1828 N. Higley Rd # 116, Mesa, AZ 85205 and Britt
Ide, an individual (“Director”). This Agreement replaces and supersedes any previous Board of Directors Agreements between
Company and Director still in effect on the Effective Date.

 

1. Term

 

This Agreement shall continue for a period of
up to twelve (12) months from the Effective Date, or earlier in the event of an annual shareholders meeting, and shall continue thereafter
for as long as Director is elected as a member of the Board of Directors by the shareholders of the Company on a yearly basis. If re-elected,
this Agreement may be renewed for successive one year terms on the same or different terms. If Director is not duly re-appointed by shareholder
vote, Director’s term will end ten (10) calendar days following the annual shareholders meeting.

 

2. Position and Responsibilities

 

		(a)	Position. The Board of Directors hereby appoints the
                                            Director to serve as a Board Member until the 2023 annual shareholders meeting or the Director’s
                                            earlier resignation, removal or death. The Director shall perform such duties and responsibilities
                                            as are customarily related to such position in accordance with Company’s bylaws and
                                            applicable law, including, but not limited to, those services described on Exhibit
                                            A attached hereto (the “Services”).  Director hereby agrees
                                            to use his/her best efforts to provide the Services.  Director shall not allow any other
                                            person or entity to perform any of the Services for or instead of Director.  Director
                                            shall comply with the statutes, rules, regulations and orders of any governmental or quasi-governmental
                                            authority, which are applicable to the Company and the performance of the Services, and Company’s
                                            rules, regulations, and practices as they may from time-to-time be adopted or modified.

 

		(b)	Other Activities. Director may be employed by another
                                            company, may serve on other Boards of Directors or Advisory Boards, and may engage in any
                                            other business activity (whether or not pursued for pecuniary advantage), as long as such
                                            outside activities do not violate Director’s obligations under this Agreement or Director’s
                                            fiduciary obligations to the Company’s shareholders. The ownership of less than a 5%
                                            interest in an entity, by itself, shall not constitute a violation of this duty. Director
                                            represents that Director has no outstanding agreement or obligation that is in conflict with
                                            any of the provisions of this Agreement, and Director agrees to use his best efforts to avoid
                                            or minimize any such conflict and agrees not to enter into any agreement or obligation that
                                            could create such a conflict without the approval of a majority of the Board of Directors.
                                            If, at any time, Director is required to make any disclosure or take any action that may
                                            conflict with any of the provisions of this Agreement, Director will promptly notify the
                                            Board of such obligation, prior to making such disclosure or taking such action.

 

    	 		 

    	 

    

 

		(c)	No Conflict. Director will not engage in any activity
                                            that creates an actual or perceived conflict of interest with Company, regardless of whether
                                            such activity is prohibited by Company’s conflict of interest guidelines or this Agreement,
                                            and Director agrees to notify the Board of Directors before engaging in any activity that
                                            could reasonably be assumed to create a potential conflict of interest with Company. Notwithstanding
                                            the provisions of Section 2(b) hereof, Director shall not engage in any activity that is
                                            in direct competition with the Company or serve in any capacity (including, but not limited
                                            to, as an employee, consultant, advisor or director) in any company or entity that competes
                                            directly or indirectly with the Company, as reasonably determined by a majority of Company’s
                                            disinterested board members, without the approval of the Board of Directors.

 

3. Compensation and Benefits

 

		(a)	Equity Compensation. In consideration of the
                                            services rendered under this Agreement, Company shall issue Director quarterly equity compensation
                                            in the form of a Notice of Grant for $40,000 worth of Restricted Stock Units (“RSU’s”)
                                            each quarter. The number of RSU’s granted shall be calculated by dividing $40,000 by
                                            the closing share price on the final trading day of each financial quarter from September
                                            30, 2022 until the 2023 annual shareholder meeting. Such RSU’s shall be fully vested
                                            at the time of grant, subject to the conditions of Section 3 (c) below.

 

		(b)	IPO Bonus.  In recognition of Director’s
                                            efforts in helping the Company achieve public listing, Company shall grant Director an additional
                                            $25,000 worth of RSU’s. The IPO Bonus RSU’s will be granted as fully vested
                                            RSU’s via a Notice of Grant subject to Section 3 (c) below.

 

 

 

		(c)	Delayed Notice of Grant. The RSU
                                            Grants under Section 3 (a) and (b) above are subject to (i) corporate reorganization to parent
                                            public holding company Atlis, Inc or another named public holding company (“Pubco”);
                                            (ii) the Pubco’s stockholders approving the Pubco Equity Plan (“Stockholder
                                            Approval”) and (iii) approval of the terms and conditions of such award by the
                                            Committee (“Committee Approval”).  In order to receive the RSU Grant,
                                            you must remain in service as a Director of the Company or its affiliates through the dates
                                            of Stockholder Approval and Committee Approval.  The RSU Grant will vest on the final
                                            trading day of the week following Stockholder Approval and Committee Approval and will be
                                            subject to the Pubco Equity Plan and the RSU Grant award agreement.  For these purposes,
                                            the term “Committee” means the board of directors or its delegate, as
                                            provided under the equity incentive plan (the “Pubco Equity Plan”) intended
                                            to be adopted by the Company, its parent or subsidiary, or its successor. Equity Compensation
                                            and IPO Bonus RSU’s (“Delayed Equity Compensation”) for which the
                                            Notice of Grant has been delayed shall be calculated by dividing the total delayed equity
                                            compensation and IPO Bonus value by the closing share price on the final trading day of the
                                            first week after the Company’s Pubco Equity Plan has been approved (“Grant Date”).
                                            Delayed Equity Compensation shall be considered fully vested on the Grant Date.

 

    	 		 

    	 

    

 

		(d)	Stipend. In addition
                                            to quarterly equity compensation, Director shall be paid a $10,000 quarterly cash stipend
                                            at the closing of each financial quarter. One stipend payment shall be payable within ten
                                            (10) calendar days of the Signing Date, and subsequent stipend payments shall be due within
                                            ten (10) calendar days of the financial quarter closing dates (December 31, 2022, March 31,
                                            2023, June 30, 2023) until the 2023 annual shareholder meeting). 

 

		(e)	Expenses.
                                            The Company shall reimburse Director for all reasonable business expenses incurred in the
                                            performance of the Services in accordance with Company’s expense reimbursement guidelines.
                                            

 

		(f)	Indemnification. Company
                                            will indemnify and defend Director against any liability incurred in the performance of the
                                            Services to the fullest extent authorized in Company’s Articles of Incorporation, as
                                            amended, bylaws, as amended and applicable law. Company agrees to maintain a Director’s
                                            and Officer’s (D&O) insurance policy to further indemnify Director against any
                                            liability incurred in the performance of her duties as a director. Company agrees to notify
                                            Director of any changes in the D&O policy within 30 days of such change being effectuated.
                                            Company agrees to furnish Director with a current copy of each D&O policy.

 

		(g)	Records.
                                            So long as the Director shall serve as a member of the Company’s Board of Directors
                                            the Director shall have full access to books and records of Company and access to management
                                            of the Company.

 

4. Termination

 

		(a)	Right to Terminate. At any time, Director may be removed
                                            as Board Member as provided in Company’s Articles of Incorporation, as amended, bylaws,
                                            as amended, and applicable law. Director may resign as Board Member or Director as provided
                                            in Company’s Articles of Incorporation, as amended, bylaws, as amended, and applicable
                                            law. Notwithstanding anything to the contrary contained in or arising from this Agreement
                                            or any statements, policies, or practices of Company, neither Director nor Company shall
                                            be required to provide any advance notice or any reason or cause for termination of Director’s
                                            status as Board Member, except as provided in Company’s Articles of Incorporation,
                                            as amended, Company’s bylaws, as amended, and applicable law.

 

    	 		 

    	 

    

 

		(b)	Effect of Termination as Director. Upon Director’s
                                            termination this Agreement will terminate; Company shall pay to Director all compensation
                                            and expenses to which Director is entitled up through the date of termination; and Director
                                            shall be entitled to her rights under any other applicable law. Thereafter, all of Company’s
                                            obligations under this Agreement shall cease.

 

5. Termination Obligations

 

		(a)	Director agrees that all property, including, without limitation,
                                            all equipment, tangible proprietary information, documents, records, notes, contracts, and
                                            computer-generated materials provided to or prepared by Director incident to the Services
                                            and her membership on the Company’s Board of Directors or any committee therefore the
                                            sole and exclusive property of the Company and shall be promptly returned to the Company
                                            at such time as the Director is no longer a member of the Company’s Board of Directors.

 

		(b)	Upon termination of this Agreement, Director shall be deemed
                                            to have resigned from all offices then held with Company by virtue of her position as Board
                                            Member. Director agrees that following any termination of this Agreement, he shall cooperate
                                            with Company in the winding up or transferring to other directors of any pending work and
                                            shall also cooperate with Company (to the extent allowed by law, and at Company’s expense)
                                            in the defense of any action brought by any third party against Company that relates to the
                                            Services.

 

6. Nondisclosure Obligations

 

Director shall maintain in confidence and shall
not, directly or indirectly, disclose or use, either during or after the term of this Agreement, any Confidential Information (as defined
below) or trade secrets belonging to Company, whether or not it is in written or permanent form, except to the extent necessary to perform
the Services, as required by a lawful government order or subpoena, or as authorized in writing by Company. These nondisclosure obligations
also apply to Proprietary Information belonging to customers and suppliers of Company, and other third parties, learned by Director as
a result of performing the Services. “Confidential Information” means all information pertaining in any manner to
the business of Company, unless (i) the information is or becomes publicly known through lawful means; (ii) the information was part
of Director’s general knowledge prior to her relationship with Company; or (iii) the information is disclosed to Director without
restriction by a third party who rightfully possesses the information and did not learn of it from Company.

 

7. Dispute Resolution

 

		(a)	Mediation. In the event of a dispute between Director
                                            and Company, the parties agree to exercise good faith efforts to negotiate a resolution.
                                            If the parties are unable to resolve the dispute themselves, they agree to employ a mutually
                                            agreeable third party mediator. Parties agree to participate in the mediation in good faith
                                            in an attempt to resolve the conflict in advance of initiating litigation.

 

    	 		 

    	 

    

 

		(b)	Jurisdiction and Venue. The parties agree that any
                                            suit, action, or proceeding between Director and Company (and its affiliates, shareholders,
                                            directors, officers, employees, members, agents, successors, attorneys, and assigns) relating
                                            to this Agreement shall be brought in either the United States District Court for the State
                                            of Arizona or in an Arizona state court and that the parties shall submit to the jurisdiction
                                            of such court. The parties irrevocably waive, to the fullest extent permitted by law, any
                                            objection the party may have to the laying of venue for any such suit, action or proceeding
                                            brought in such court. If any one or more provisions of this Section shall for any reason
                                            be held invalid or unenforceable, it is the specific intent of the parties that such provisions
                                            shall be modified to the minimum extent necessary to make it or its application valid and
                                            enforceable.

 

		(c)	Attorneys’ Fees. Should any litigation, arbitration
                                            or other proceeding be commenced between the parties concerning the rights or obligations
                                            of the parties under this Agreement, the party prevailing in such proceeding shall be entitled,
                                            in addition to such other relief as may be granted, to a reasonable sum as and for its attorneys’
                                            fees in such proceeding. This amount shall be determined by the court in such proceeding
                                            or in a separate action brought for that purpose. In addition to any amount received as attorneys’
                                            fees, the prevailing party also shall be entitled to receive from the party held to be liable,
                                            an amount equal to the attorneys’ fees and costs incurred in enforcing any judgment
                                            against such party. This Section is severable from the other provisions of this Agreement
                                            and survives any judgment and is not deemed merged into any judgment.

 

8. Entire Agreement

 

This Agreement constitutes the entire understanding
between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning
the Agreement.

 

9. Amendments; Waivers

 

This Agreement may be amended, modified, superseded
or canceled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument
executed by the parties or, in the case of a waiver, by the party to be charged.  Any amendment or waiver by the Company must be
approved by the Company’s Board of Directors and executed on behalf of the Company by its Chief Executive Officer.  If the
Director shall also serve as Chief Executive Officer, such amendment or waiver must be executed on behalf of the Company by an officer
designed by the Company’s Board of Directors.

 

10. Assignment

 

This Agreement shall not be assignable by either
party.

 

    	 		 

    	 

    

 

11. Severability

 

If any provision of this Agreement shall be held
by a court to be invalid, unenforceable, or void, such provision shall be enforced to fullest extent permitted by law, and the remainder
of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a
court of competent jurisdiction to exceed the maximum time period or scope that such court deems enforceable, then such court shall reduce
the time period or scope to the maximum time period or scope permitted by law.

 

12. Governing Law

 

This Agreement shall be governed by and construed
in accordance with the laws of the State of Arizona.

 

13. Interpretation

 

This Agreement shall be construed as a whole,
according to its fair meaning, and not in favor of or against any party. Captions are used for reference purposes only and should be
ignored in the interpretation of the Agreement.

 

14. Binding Agreement

 

Each party represents and warrants to the other
that the person(s) signing this Agreement below has authority to bind the party to this Agreement and that this Agreement will legally
bind both Company and Director. To the extent that the practices, policies, or procedures of Company, now or in the future, are inconsistent
with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Director’s duties or
compensation as Board Member will not affect the validity or scope of the remainder of this Agreement.

 

15. Mutual Non-Disparagement

 

Director and the Company mutually agree to forbear
from making, causing to be made, publishing, ratifying, or endorsing any and all disparaging remarks, derogatory statements or comments
made to any party with respect to either of them. Further, the Parties agree to forbear from making any public or non-confidential statement
with respect to any claim or complaint against either party without the mutual consent of each party, to be given in advance of any such
statement.

 

16. Director Acknowledgment

 

Director acknowledges Director has had the opportunity
to consult legal counsel concerning this Agreement, that Director has read and understands the Agreement, that Director is fully aware
of its legal effect, and that Director has entered into it freely based on her own judgment and not on any representations or promises
other than those contained in this Agreement.

 

    	 		 

    	 

    

 

17. Cooperation

 

In the event of any claim or litigation against
the Company and/or Director based upon any alleged conduct, acts or omissions of Director during the tenure of Director as an officer
of the Company, whether known or unknown, threatened or not as of the time of this writing, the Company will cooperate with Director
and provide to Director such information and documents as are necessary and reasonably requested by Director or her counsel, subject
to restrictions imposed by federal or state securities laws or court order or injunction. The Company shall cooperate in all respects
to ensure that Director has access all available insurance coverage and shall do nothing to damage Director’s status as an insured,
and shall provide all necessary information for Director to make or tender any claim under applicable coverage.

 

18. Counterparts

 

This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

19. Date of Agreement

 

The parties have duly signed this Agreement as
of November 11, 2022 with an effective date of September 27, 2022.

 

20. Signatures

 

 

	 	ATLIS MOTOR VEHICLES, INC.	 	 	Britt Ide	 
	 	a Delaware Corporation	 	 	Individual	 
	 	 	 	 	 	 
	 	/s/ Mark
    Hanchett	 	 	/s/ Britt
    Ide	 
	Name	Mark Hanchett	 	Name	Britt Ide	 
	Title	CEO	 	Title	Director	 

 

    	 		 

    	 

    

 

EXHIBIT A

 

DESCRIPTION OF SERVICES

 

Responsibilities as Director. Director shall have all responsibilities
of a Director of the Company imposed by Delaware, Arizona, or other applicable law, the Articles of Incorporation, as amended, and Bylaws,
as amended, of Company. These responsibilities shall include, but shall not be limited to, the following:

 

		1.	Attendance.
                                            Use best efforts to attend regularly scheduled and special meetings of Company’s Board
                                            of Directors, along with Committee Meetings. Company will conduct four (4) in-person quarterly
                                            board meetings and Committee Meetings as regularly scheduled, but may call special board
                                            meetings as necessary. Special board meetings shall be conducted on an as-needed basis
                                            via remote teleconference.

 

		2.	Executive Sessions. From time to time, and especially
                                            during the term of this agreement, the Chairman of the Board may call Executive Sessions
                                            or emergency board meetings. Director will be expected to participate in such meetings, as
                                            necessary.

 

		3.	Consult.  Meet with the Company upon request to discuss
                                            any matter involving the Company or its Subsidiaries, which may involve issues of which the
                                            Director has knowledge or expertise. Director acknowledges and agrees that the Company may
                                            rely upon Director’s expertise in any business discipline where Director has knowledge
                                            and/or experience that may contribute to the facilitation of Company’s operations.
                                            Director acknowledges that such requests may involve substantial time and efforts.

 

		4.	Act as a Fiduciary. Represent the shareholders and the
                                            interests of Company as a fiduciary; and

 

		5.	Participation. Participate as a full voting member of
                                            Company’s Board of Directors in setting overall objectives, approving plans and programs
                                            of operation, formulating general policies, offering advice and counsel, serving on Board
                                            Committees, and reviewing management performance.

 

		6.	Commitment. Based upon the foregoing responsibilities,
                                            Director shall be expected to commit an average of at least 10 hours per month to Company
                                            business. Director shall not be expected to dedicate more than 15 hours of time to Company
                                            business per month.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]